

Substitute Form PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 13227-008001		Application No. 09/759,371	
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))				Applicant Michael F. Holick et al.		Filing Date January 16, 2001	
				Group Art Unit 16147623		Filing Date If Appropriate	

RECEIVED  
MAR 25 2002  
TECH CENTER 16001293

Stamp: OIPF MAR 21 2002

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
VKF	AA1	3,733,318	05/15/73	Marx	540	63	


Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
VKF	AB1	0 721 956	07/17/96	EP				
VKF	AC1	0 123 485	10/31/84	EP				
VKF	AD1	94/15947	7/21/94	WIPO				
VKF	AE1	93/21198	10/28/93	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
VKF	AF1	Althaus, et al., "Separation of some natural and synthetic corticosteroids in biological fluids and tissues by high-performance liquid chromatography" (chemical abstract no. 136023, vol. 96, no. 17, 1982) <i>J. Chromatogr. 1982, 227 (1), 11-23. Abstract only.</i>
VKF	AG1	International Search Report for PCT/GB 01/00146; mailed December 5, 2001
VKF	AH1	Mattox, et al., "Synthesis of C-21 glucosiduronates of cortisone and related corticosteroids" (chemical abstract no. 13321, vol. 71, no. 3, 1969) <i>Biochemistry 1969, 8(3), 1188-89. Abstract only.</i>

Examiner Signature <i>RRonda</i>	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13227-008001	Application No. 09/759,371
	Applicant Michael F. Holick et al.		
	Filing Date January 16, 2001	Group Art Unit <del>1614</del> 7623	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
KCF	AA	6,150,336	11/21/2000	Deninno et al.	514	26	
KCF	AB	6,090,949	07/18/2000	McGill, III et al.	549	51	
KCF	AC	6,090,843	07/18/00	Bryant et al.	514	443	
KCF	AD	6,020,315	02/01/2000	Bosslet et al.	514	34	
KCF	AE	5,972,383	10/26/1999	Gibson et al.	424	464	
KCF	AF	5,955,100	09/21/1999	Bosslet et al.	424	450	
KCF	AG	5,935,995	08/10/1999	Bosslet et al.	514	460	
KCF	AH	5,908,833	06/01/1999	Brattsand et al.	514	26	
KCF	AI	5,904,930	05/18/99	Fischer et al.	424	448	
KCF	AJ	5,902,582	05/11/99	Hung	424	130.1	
KCF	AK	5,877,219	03/02/1999	Wilson	514	617	
KCF	AL	5,872,114	02/16/1999	Labrie	514	178	
KCF	AM	5,856,314	01/05/1999	Kaas et al.	514	89	
KCF	AN	5,855,905	01/05/1999	Oettel et al.	424	426	
KCF	AO	5,852,059	12/22/1998	Thompson	514	648	
KCF	AP	5,846,976	12/08/98	Batchelor et al.	514	284	
KCF	AQ	5,844,001	12/01/1998	McClay et al.	514	648	
KCF	AR	5,843,984	12/01/1998	Clay et al.	514	443	
KCF	AS	5,843,974	12/01/98	Swift	514	370	
KCF	AT	5,843,964	12/01/1998	Boss	514	324	
KCF	AU	5,843,962	12/01/1998	Dodge	514	324	
KCF	AV	5,843,914	12/01/1998	Johnson, Jr. et al.	514	44	
KCF	AW	5,827,892	10/27/98	Löser et al.	514	648	
KCF	AX	5,827,844	10/27/1998	Cullinan et al.	514	176	
KCF	AY	5,821,254	10/13/1998	Sporn et al.	514	324	
KCF	AZ	5,814,603	09/29/1998	Oldenburg et al.	514	12	
KCF	AAA	5,811,120	09/22/1998	Gibson et al.	424	464	

Examiner Signature 	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13227-008001	Application No. 09/759,371
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Michael F. Holick et al.	
		Filing Date January 16, 2001	Group Art Unit <del>1614</del> 1623
(37 CFR §1.98(b))			

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
KCF	ABB	5,808,061	09/15/1998	Dodge et al.	540	602	
KCF	ACC	5,807,899	09/15/1998	Bohlmann et al.	514	708	
KCF	ADD	5,795,883	08/18/1998	Hesch et al.	514	172	
KCF	AEE	5,770,612	06/23/1998	Fontana	514	324	
KCF	AFF	5,763,611	06/09/1998	Kaas et al.	546	21	
KCF	AGG	5,753,639	05/19/1998	Labrie	514	169	
KCF	AHH	5,753,634	05/19/1998	Ebetino et al.	514	81	
KCF	AII	5,753,633	05/19/1998	Gaffar	514	79	
KCF	AJJ	5,747,510	05/05/1998	Draper	514	333	
KCF	AKK	5,731,342	03/24/1998	Cullinan et al.	514	443	
KCF	ALL	5,731,327	03/24/98	Luke	514	324	
KCF	AMM	5,726,168	03/10/98	Cullinan et al.	514	176	
KCF	ANN	5,719,136	02/17/98	Chwalisz et al.	514	170	
KCF	AOO	5,712,396	01/27/1998	Magnin et al.	546	22	
KCF	APP	5,710,285	01/20/98	Hauser et al.	549	4	
KCF	AQQ	5,708,010	01/13/1998	Glasebrook	514	324	
KCF	ARR	5,700,815	12/23/1997	Calnek et al.	514	324	
KCF	ASS	5,698,572	12/16/1997	Dodge	514	324	
KCF	ATT	5,693,656	12/02/1997	Black et al.	514	324	
KCF	AUU	5,691,355	11/25/97	Bryant et al.	514	324	
KCF	AVV	5,688,812	11/18/1997	Cullinan	514	324	
KCF	AWW	5,686,476	11/11/1997	May	514	324	
KCF	AXX	5,686,468	11/11/1997	Cullinan	514	324	
KCF	AYY	5,686,467	11/11/1997	Bumol et al.	514	324	
KCF	AZZ	5,672,610	09/30/1997	Zuckerman	514	324	
KCF	AAAA	5,668,120	09/16/1997	Shinoda et al.	514	102	
KCF	ABBB	5,663,184	09/02/1997	Bryant et al.	514	324	

Examiner Signature 	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13227-008001	Application No. 09/759,371
	Applicant Michael F. Holick et al.		
	Filing Date January 16, 2001	Group Art Unit <del>1614</del> 1623	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
KCF	ACCC	5,659,087	08/19/97	Aikins et al.	568	27	
KCF	ADDD	5,658,931	08/19/97	Bryant et al.	514	319	
KCF	AEEE	5,646,137	07/08/1997	Black et al.	514	171	
KCF	AFFF	5,641,790	06/24/1997	Draper	514	333	
KCF	AGGG	5,635,495	06/03/1997	White et al.	514	81	
KCF	AHHH	5,629,425	05/13/97	LaBell et al.	546	202	
KCF	AIHH	5,629,303	05/13/1997	Labrie et al.	514	169	
KCF	AJJJ	5,622,975	04/22/1997	Singh et al.	514	324	
KCF	AKKK	5,616,571	04/01/1997	Daifotis et al.	514	102	
KCF	ALLL	5,612,317	03/18/1997	Holick	514	26	
KCF	AMMM	5,610,168	03/11/1997	Draper	514	333	
KCF	ANNN	5,610,167	03/11/1997	Cullinan	514	324	
KCF	AOOO	5,610,166	03/11/1997	Singh	514	324	
KCF	APPP	5,602,115	02/11/1997	Nugent	514	105	
KCF	AQQQ	5,593,987	01/14/1997	Cullinan et al.	514	217.03	
KCF	ARRR	5,591,753	11/26/1996	Black et al.	514	324	
KCF	ASSS	5,578,614	11/26/1996	Bryant et al.	514	324	
KCF	ATTT	5,569,772	10/29/1996	Hoard et al.	549	52	
KCF	AUUU	5,567,820	10/22/1996	Dodge et al.	546	202	
KCF	AVVV	5,563,054	10/08/1996	Briggs et al.	435	127	
KCF	AWWW	5,552,417	09/03/1996	Dodge	514	324	
KCF	AXXX	5,552,416	09/03/1996	Keohane	514	324	
KCF	AYYY	5,550,123	08/27/1996	Cullinan	514	217.03	
KCF	AZZZ	5,545,641	08/13/1996	Bruns, Jr. et al.	514	317	
KCF	AAAAA	5,545,634	08/13/1996	Labrie	514	169	
KCF	ABBBB	5,540,925	07/30/1996	Mikulski et al.	424	94.6	
KCF	ACCCC	5,534,526	07/09/1996	Cullinan	514	324	

Examiner Signature <i>29200nda</i>	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office		Attorney's Docket No. 13227-008001	Application No. 09/759,371
	Applicant Michael F. Holick et al.			
	Filing Date January 16, 2001		Group Art Unit 1614 1623	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
KKF	ADDD	5,530,010	06/25/1996	Glasebrook	514	317	
KKF	AEEEE	5,525,624	06/11/1996	Gitter et al.	514	443	
KKF	AFFFF	5,521,214	05/28/1996	Bryant et al.	514	443	
KKF	AGGGG	5,521,198	05/28/1996	Zuckerman	514	324	
KKF	AHHHH	5,514,826	05/07/1996	Hoard et al.	556	428	
KKF	AIIII	5,512,296	04/30/1996	Cullinan	424	451	
KKF	AJJJJ	5,510,358	04/23/1996	Palkowitz	514	324	
KKF	AKKKK	5,508,392	04/16/1996	Holick	536	18.1	
KKF	ALLLL	5,508,292	04/16/1996	Sall et al.	514	324	
KKF	AMMMM	5,502,074	03/26/1996	Cullinan et al.	514	443	
KKF	ANNNN	5,496,851	03/05/1996	Grinnell	514	443	
KKF	AOOOO	5,496,828	03/05/1996	Cullinan	514	324	
KKF	APPPP	5,494,920	02/27/1996	Glasebrook et al.	514	324	
KKF	AQQQQ	5,492,927	02/20/1996	Gitter et al.	514	443	
KKF	ARRRR	5,491,173	02/13/1996	Toivola et al.	514	648	
KKF	ASSSS	5,486,511	01/23/1996	Weintraub et al.	514	178	
KKF	ATTTT	5,484,797	01/16/1996	Bryant et al.	514	319	
KKF	AUUUU	5,478,847	12/26/1995	Draper	514	333	
KKF	AVVVV	5,470,883	11/28/1995	Stromberg	514	648	
KKF	AWWWW	5,466,810	11/14/95	Godfrey	546	202	
KKF	AXXXX	5,457,117	10/10/1995	Black et al.	514	337	
KKF	AYYYY	5,455,335	10/03/95	Kahne et al.	536	5	
KKF	AZZZZ	5,447,941	09/05/1995	Zuckerman	514	324	
KKF	AAAAA	5,446,203	08/29/95	McNelis	568	322	
KKF	ABBBB	5,446,053	08/29/95	Keohane	514	324	
KKF	ACCCC	5,441,964	08/15/1995	Bryant et al.	514	324	
KKF	ADDDD	5,439,931	08/08/1995	Sales	514	443	


Examiner Signature 	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13227-008001	Application No. 09/759,371
		Applicant Michael F. Holick et al.	
		Filing Date January 16, 2001	Group Art Unit 1614 1623

**Information Disclosure Statement  
by Applicant**  
(Use several sheets if necessary)

(37 CFR §1.98(b))

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
KKF	AEEEE	5,428,181	06/27/1995	Sugioka et al.	552	506	
KKF	AFFFF	5,418,252	05/23/1995	Williams	514	443	
KKF	AGGGG	5,409,911	04/25/1995	Tyler et al.	514	91	
KKF	AHHHH	5,403,829	04/04/1995	Lehtinen et al.	514	102	
KKF	AIIII	5,393,763	02/28/1995	Black et al.	514	333	
KKF	AJJJJ	5,362,720	11/08/1994	Labrie	514	169	
KKF	AKKKK	5,360,797	11/01/1994	Johnson et al.	514	111	
KKF	ALLLL	5,338,731	08/16/1994	Breuer et al.	514	168	
KKF	AMMMM	5,317,015	05/31/1994	Ullrich et al.	514	79	
KKF	ANNNN	5,312,954	05/17/1994	Breuer et al.	558	161	
KKF	AOOOO	5,260,065	11/09/1993	Mathur et al.	424	450	
KKF	APPPP	5,196,435	03/23/1993	Clemens et al.	514	284	
KKF	AQQQQ	5,196,409	03/23/1993	Breuer et al.	514	108	
KKF	ARRRR	5,192,525	03/09/1993	Yang et al.	424	1.1	
KKF	ASSSS	5,189,212	02/23/1993	Ruenitz	562	468	
KKF	ATTTT	5,183,815	02/02/1993	Saari et al.	514	172	
KKF	AUUUU	5,157,027	10/20/1992	Biller et al.	514	107	
KKF	AVVVV	5,118,667	06/02/1992	Adams et al.	514	12	
KKF	AWWWW	5,103,036	04/07/1992	Magnin et al.	558	161	
KKF	AXXXX	5,024,833	06/18/1991	Del Bianco et al.	424	161	
KKF	AYYYY	4,897,503	01/30/1990	Asao et al.	558	155	
KKF	AZZZZ	4,894,373	01/16/90	Young	514	239.2	
KKF	AAAAA	4,888,331	12/19/1989	Elger et al.	514	170	
KKF	ABBBB	4,851,433	07/25/1989	Kraus	514	648	
KKF	ACCCCC	4,810,486	03/07/1989	Kelly et al.	429	1.1	
KKF	ADDDDD	4,803,227	02/07/1989	Brandes et al.	514	651	
KKF	AEEEE	4,696,949	09/29/1987	Toivola et al.	514	648	

Examiner Signature 	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13227-008001	Application No. 09/759,371
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Michael F. Holick et al.	
		Filing Date January 16, 2001	Group Art Unit <del>1614</del> 1623
(37 CFR §1.98(b))			

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
KKF	AAAAAAA	4,656,187	04/07/1987	Black et al.	514	422	
KKF	AGGGGGG	4,623,660	11/18/86	Richardson	514	514	
KKF	AHHHHHH	4,536,516	08/20/1985	Harper et al.	514	574	
KKF	AIIIIII	4,521,410	06/04/1985	Holick et al.	514	26	
KKF	AJJJJJJ	4,418,068	11/29/1983	Jones	514	337	
KKF	AKKKKKK	4,329,296	05/11/1982	Tax	552	621	
KKF	ALLLLLL	4,310,523	01/12/1982	Neumann	424	240	
KKF	AMMMMMM	4,292,251	09/29/1981	Overbeek	552	629	
KKF	ANNNNNN	4,220,599	09/02/1980	van der Vies	552	638	
KKF	AOOOOOO	4,198,435	04/15/80	Richardson	514	651	
KKF	APPPPPP	3,983,144	09/28/1976	Leemhuis	552	650	
KKF	AQQQQQQ	3,966,713	06/29/1976	Hofmeister et al.	514	172	
KKF	ARRRRRR	3,944,576	03/16/1976	van den Broek et al.	552	617	
KKF	ASSSSSS	3,929,768	12/30/1975	Brattsand et al.	540	63	
KKF	ATTTTTT	3,917,831	11/04/1975	Grunwell et al.	514	178	
KKF	AUUUUUU	3,862,193	01/21/1975	Hirsch	552	520	
KKF	AVVVVVV	3,721,712	03/20/73	Palopoli et al.	564	323	
KKF	AWWWWWW	3,427,300	02/11/69	Sarett et al.	536	17.2	
KKF	AXXXXXX	3,134,718	05/26/1964	Nobile et al.	514	172	
KKF	AYYYYYY	3,126,375	03/24/64	Ringold et al.	540	70	
KKF	AZZZZZZ	3,124,571	03/10/1964	Ringold et al.	435	53	
KKF	AAAAAAA	3,104,246	11/17/1963	Amiard et al.	552	595	
KKF	ABBBBBB	3,053,865	09/11/1962	Taub et al.	552	528	
KKF	ACCCCCC	3,053,832	09/11/1962	Gould	540	97	
KKF	ADDDDDD	3,021,347	02/13/62	Allen et al.	74	574	
KKF	AEEEEEE	3,014,938	12/26/1961	Mills et al.	552	565	
KKF	AFFFFFFF	3,007,923	11/07/61	Muller et al.	540	35	

Examiner Signature <i>RKD</i>	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13227-008001	Application No. 09/759,371
	Applicant Michael F. Holick et al.		
	Filing Date January 16, 2001	Group Art Unit 1614 1623	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
KCF	AGGGGGGG	2,897,218	07/28/1959	Sebek	552	572	
KCF	AHHHHHHH	2,897,216	07/28/1959	Oliveto, et al.	552	568	
KCF	AIIIIIII	2,837,464	06/03/1958	Nobile	435	61	
KCF	AJJJJJJJ	2,789,118	04/16/1957	Bernstein et al.	552	566	
KCF	AKKKKKKK	2,602,769	07/08/1952	Murray et al.	435	60	
KCF	ALLLLLLL	2,447,325	08/17/48	Gallagher	552	548	
KCF	AMMMMMMM	2,403,683	07/09/1946	Reichstein	552	535	

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
KCF	ANNNNNNN	WO 01/27129	04/19/2001	WIPO				
KCF	AOOOOOOO	WO 01/27127	04/19/2001	WIPO				
KCF	APPPPPPP	WO 00/66612	11/09/2000	WIPO				
KCF	AQQQQQQQ	EP 0 721 956 B1	08/22/2000	EP				
KCF	ARRRRRRR	WO 99/07693	02/18/1999	WIPO				
KCF	ASSSSSSS	EP 0 890 643 A2	01/13/99	EP				
KCF	ATTTTTTT	WO 99/00019	01/07/1999	WIPO				
KCF	AUUUUUUU	EP 0 879 605 A2	11/25/98	EP				
KCF	AVVVVVVV	EP 0 795 334 A2	09/17/97	EP				
KCF	AWWWWWWW	WO 96/40616	12/19/1996	WIPO				
KCF	AXXXXXXX	EP 0 735 141 A2	10/02/96	EP				
KCF	AYYYYYYY	WO 96/03995	02/15/1996	WIPO				
KCF	AZZZZZZZ	EP 0 683 170 A1	11/22/1995	Europe				
KCF	AAAAAAAA	95/26720	10/12/1995	WIPO				
KCF	ABBBBBBB	WO 95/11699	05/04/1995	WIPO				
KCF	ACCCCCCC	82 273 873 A	07/06/1994	UK				


Examiner Signature <i>R.R. Onda</i>	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13227-008001	Application No. 09/759,371
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))		Applicant Michael F. Holick et al.	
		Filing Date January 16, 2001	Group Art Unit 1614 1623

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
KCF	ADDDDDDD	EP 0 595 133 A2	05/04/94	EP				
KCF	AEEEEEEE	WO 93/22334	11/11/1993	WIPO				
KCF	AFFFFFFF	WO 93/00123	01/07/1993	WIPO				
KCF	AGGGGGGG	WO 92/06068	04/16/1992	WIPO				
KCF	AHHHHHHH	WO 92/04365	03/19/1992	WIPO				
KCF	AIIIIIII	WO 90/10638	09/20/1990	WIPO				
KCF	AJJJJJJJ	63-7331	01/13/88	Japan				
KCF	AKKKKKKK	62-4527	01/10/87	Japan				
KCF	ALLLLLLL	WO 84/04041	10/25/1984	WIPO				
KCF	AMMMMMMM	AU-B-20504/83	05/03/1984	Australia				
KCF	ANNNNNNN	EP 0 011 372 B1	02/09/83	EP				
KCF	AOOOOOOO	0 062 503 A1	10/13/1982	EP				
KCF	APPPPPPP	GB 1 338 547	11/28/1973	Great Britain				
KCF	AQQQQQQQ	GB 1 175 219	12/23/1969	Great Britain				
KCF	ARRRRRRR	1,059,548	02/22/67	United Kingdom				
KCF	ASSSSSSS	1,015,396	12/31/65	United Kingdom				
KCF	ATTTTTTT	GB 916 778	01/30/1963	Great Britain				
	AUUUUUUU	UK 584,062	12/27/1944	UK				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
KCF	AVVVVVVV	Astrom, E. and Soderhall, S., "Beneficial effect of Bisphosphonate during five years of treatment of severe osteogenesis imperfecta," <i>Acta Paediatr.</i> 97:64-68, Scandinavian University Press (1998)
KCF	AWWWWWWW	Bals-Pratsch et al., "Substitution of hypogonadal men with transdermal testosterone over one year" <i>Acta Endocrinologica</i> 118: 7-13 (1988)
KCF	AXXXXXXX	Becker, D., and Galili, N., "A Novel Synthesis of Protected Glucose Intermediates," <i>Tetrahedron Lett.</i> 33:4775-4778 (1992).
KCF	AYYYYYYY	Bergrem et al., "Prednisolone Pharmacokinetics and Protein-binding in Patients with Portosystemic Shunt" <i>Scandinavian Journal of Gastroenterology</i> Vol. 18:273-276 (1983)

Examiner Signature 	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


Substitute Form PTO-1449 (Modified)  <b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)  (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. <b>13227-008001</b>	Application No. <b>09/759,371</b>
		Applicant <b>Michael F. Holick et al.</b>	
		Filing Date <b>January 16, 2001</b>	Group Art Unit <b>1614 1623</b>

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
KCF	ZZZZZZ	Blank, M.A. et al., "Nonclinical Model for Assessing Gastric Effects of Bisphosphonates," <i>Digestive Diseases and Sciences</i> 42:281-288, Plenum Publishing Corporation (1997).
KCF	AAAAA	Bonjour, J.P. and Rizzoli, R., "Clodronate in Hypercalcemia of Malignancy," <i>Calcif. Tissue Int.</i> 46:s20-s25, Springer-Verlag (1990).
	<del>BBBBBB</del>	<del>Catlin, D.H., "Anabolic Steroids," in <i>Endocrinology</i> - Volume 3, ed's DeGroot et al., pp. 2362-2376- (1995)</del>
KCF	ACCCCCC	Clissold et al., "Budesonide A Preliminary Review of its Pharmacodynamic Properties and Therapeutic Efficacy in Asthma and Rhinitis" <i>Drugs</i> 28:485-518 (1984)
KCF	ADDDDDDD	Coleman, R.E., "How can we improve the treatment of bone metastasis further?" <i>Curr. Opin. Oncol.</i> 10:s7-s13, Lippincott Williams & Wilkins (1998).
KCF	AEeeeeeee	Conrow et al., "Steroid Conjugates. VI. An Improved Koenigs-Knorr Synthesis of Aryl Glucuronides Using Cadmium Carbonate, a New and Effective Catalyst" <i>The Journal of Organic Chemistry</i> Vol 36, No. 7 (1971)
KCF	AFFFFFFF	Cui et al., "A budesonide prodrug accelerates treatment of colitis in rats" <i>Gut.</i> 1994;35:1439-1446
KCF	AGGGGGGG	Cunningham, G.R., et al., "Characterization of steroid of steroid binding specificity of the androgen receptor in human foreskin fibroblasts," <i>Steroids</i> 41:617-626 (1983).
KCF	AHHHHHHH	Cunningham, G.R., et al., "Differences in Steroid Specificity for Rat Androgen Binding Protein and the Cytoplasmic Receptor," <i>Steroids</i> 33:261-276 (1979).
	<del>AIUUUUU</del>	<del>Daggett, P.R., et al., "Oral Testosterone, A Reappraisal," <i>Hormone Res.</i> 9:121-129 (1978).</del>
KCF	AJJJJJJJ	Delbarre et al., "Ellipticine Derivatives with an Affinity to the Estrogen Receptor, and Approach to Develop Intercalating Drugs with a Specific Effect on the Hormone -Dependent Breast Cancer" <i>J. Med. Chem.</i> 1985, 28, 752-761
KCF	AKKKKKKK	Delmas, P.D. et al., "Bisphosphonate Risedronate Prevents Bone Loss in Women With Artificial Menopause Due to Chemotherapy of Breast Cancer: A Double-Blind, Placebo-Controlled Study," <i>J. Clin. Oncol.</i> 15:955-962, American Society of Clinical Oncology (1997).
KCF	ALLLLLLL	Delmas, P.D. Woolf, A.D., "Osteoporosis: outstanding issues," <i>Bailliere's Clinical Rheumatol.</i> 11:645-649, Bailliere Tindall (1997).
KCF	AMMMMMMM	Dialog File 351, Accession No. 11481631, Derwent WPI English language abstract for EP 0 795 334 A2 (Document AL2). <b>1997</b>
KCF	ANNNNNNN	Dialog File 351, Accession No. 12179761, Derwent WPI English language abstract for EP 879 605 A2 (Document AM2) <b>1997</b>
KCF	A0000000	Dialog File 351, Accession no. 9865543, Derwent WPI English language abstract for EP 0 595 133 A2 (Document AM1). <b>1998</b>
KCF	APPPPPPP	Dodge, J.A., et al., "Synthesis and Estrogen Receptor Binding Affinities of the Major Human Metabolites of Raloxfene (LY139481)," <i>Bioorg. Med. Chem. Lett.</i> 8:993-996, Pergamon Press (1997)
KCF	AQQQQQQQ	Duan et al., "Estrogen-Induced c-fos Protooncogene Expression in MCF-7 Human Breast Cancer Cells: Role of Estrogen Receptor Sp1 Complex Formation" <i>Endocrinology</i> Vol. 139 No. 4, 1981-1990
KCF	ARRRRRRR	Empey et al. "Synthesis of A Novel Glucocorticoid-Conjugate Which accelerates Colitis Healing Without Adrenal Suppression" <i>Gastroenterology</i> , Vol. 104, No. 4, Part 2(1993)

Examiner Signature <i>R2 Janda</i>	Date Considered <b>12-13-02</b>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13227-008001	Application No. 09/759,371
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Michael F. Holick et al.	
		Filing Date January 16, 2001	Group Art Unit 1614 1623
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
KCF	ASSSSSSSS	Fedorak et al., "Colonic Delivery of Dexamethasone From a Prodrug Accelerates Healing of Colitis in Rats Without Adrenal Suppression" <i>Gas.</i> , 1995;108:1688-1699
KCF	ATTTTTTTT	Fedorak, et al., "A novel colon-specific steroid prodrug enhances sodium chloride absorption in rat colitis," <i>The American Physiological Society</i> 1995 G210-G218
KCF	AUUUUUUUU	Fernandez et al., "Altered Phenotypic Characteristics of T47D Human Breast Cancer Cells After Prolonged Growth in Estrogen-Deficient Medium" <i>Cell biology International</i> 1998, Vol. 2, no. 9/10, 623-633
KCF	AVVVVVVVV	Flanagan, A.M. and Chambers, T.J., "Inhibition of Bone Resorption by Bisphosphonates: Interactions Between Bisphosphonates, Osteoclasts, and Bone," <i>Calcif. Tissue Int.</i> 49:407-415, Springer-Verlag (1991).
KCF	AWWWWWWWW	Fleisch, H., "Bisphosphonates: Pharmacology and Use in the Treatment of Tumour-Induced Hypercalcaemic and Metastatic Bone Disease," <i>Drugs</i> 42:919-944, Adis International Limited (1991).
KCF	AXXXXXXXXX	Friend et al., "A colon-Specific Drug-Delivery System Based on Drug Glycosides and the Glycosidases of Colonic Bacteria", <i>J. Med. Chem</i> 1984, 27,261-266...
KCF	AYYYYYYYY	Friend et al., "Colon-Specific drug delivery from a glucoside prodrug in the guinea-pig. Efficacy Study" <i>Journal of Controlled Release</i> , 15 (1991) 47-54
KCF	AZZZZZZZZ	Friend et al., "Drug glycosides in oral colon-specific drug delivery" <i>Journal of Controlled Release</i> , 19 (1992) 109-120
KCF	AAAAAAAAA	Friend et al., "Drug Glycosides: Potential Prodrugs for colon-Specific Drug Delivery" <i>J. Med. Chem.</i> 1985, 28,51-57
KCF	ABBBBBBBB	Friend et al., "Glycoside prodrugs: novel pharmacotherapy for colonic diseases" <i>S.T.P. Pharma Sciences</i> 5 (1) 70-76 1995
KCF	ACCCCCCCC	Friend et al., "Relative anti-inflammatory effect of oral dexamethasone- $\beta$ -D-glucoside and dexamethasone in experimental inflammatory bowel disease in guinea-pigs" <i>J. Pharm. Pharmacol.</i> 1991, 43:353-355
KCF	ADDDDDDDD	Friend et al., "Review article: issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease" <i>Aliment Pharmacol Ther</i> 1998; 12: 591-603
KCF	AEEEEEEEE	Friend, et al. "Effect of Antibiotic Pretreatment on Glycoside/Glycosidase-based Colonic Drug Delivery", <i>Drug Design and Delivery</i> , 1990, Vol. 6, pp. 311-318
KCF	AFFFFFFFF	Friend, et al., "Relative Antiinflammatory Effect of Oral Dexamethasone- $\beta$ -D-glucoside and Dexamethasone in Experimental IBD," <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</i> , 18:564-565 (1991)
KCF	AGGGGGGGG	Fukushima, et al., "Metabolism of Testosterone N-Acetylglucosaminide," <i>Steroids</i> , March 1972, 385-409
KCF	AHHHHHHHH	Ganong et al., "Endocrine Function of the Testes" <i>Endocrinology &amp; Metabolism</i> Chapter 23, 336-339, (1979)
KCF	AMMMMMM	Goodman and Gilman's "the Pharmacological Basis of Therapeutics," 8 <sup>th</sup> ed., Gilman, A.G., et al., eds., Pergamon Press, New York, NY, pp. 13-17 (1990)
KCF	AJJJJJJJJ	Gordon-Weeks, R. et al., "Structural aspects of the effectiveness of bisphosphonates as competitive inhibitors of the plant vacuolar proton-pumping pyrophosphatase," <i>Biochem. J.</i> 337-377, The Biochemical Society (February 1999.)

Examiner Signature 	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13227-008001	Application No. 09/759,371
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Michael F. Holick et al.	
		Filing Date January 16, 2001	Group Art Unit 1614 1623
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
KKF	AKKKKKKKKK	Graepel et al., "Reproduction Toxicity Studies with Pamidronate" <i>Arzneimittel Forschung Drug Research</i> 42 (i), 587-688, May 1992
KKF	ALLLLLLLLL	Graham, D.Y. et al., "Primary Amino-Bisphosphonates: A New Class of Gastrotoxic Drugs- Comparison of Alendronate and Aspirin," <i>Am. J. Gastroenterol.</i> 92:1322-1325, The American College of Gastroenterology (1997).
KKF	AMMMMMMMMM	Green, J.R. et al., "Renal Tolerability Profile of Novel, Potent Bisphosphonates in Two Short-Term Rat Models," <i>Pharmacol. Toxicol.</i> 80:225-230, Nordic Pharmacological Society (1997).
KKF	ANNNNNNNNN	Haeblerlin et al., "In Vitro Evaluation of Dexamethasone-β-D-Glucuronide for Colon-Specific Drug Delivery," <i>Pharmaceutical Research</i> , Vol. 10, No. 11, 1993
<del>_____</del>	<del>AOOOOOOOOO</del>	<del>Handelsman, D.J., "Testosterone and Other Androgens: Physiology, Pharmacology, and Therapeutic Use," in <i>Endocrinology - Volume 3</i>, ed's DeGroot et al., pp. 2351-2361 (1995)</del>
KKF	APPPPPPPPP	Harnageo-theophilus et al., "Acetaminophen-Induced Proliferation of Breast Cancer Cells Involves Estrogen Receptors" <i>Toxicology and Applied Pharmacology</i> 155:273-279 (1999).
KKF	AQQQQQQQQQ	Hirotsani et al., "Biotransformation of Testosterone and Other Androgens By Suspension Cultures of <i>Nicotiana Tabacum</i> 'Bright Yellow'" <i>Phytochemistry</i> Vol. 13 pp. 2135-2142 (1974)
KKF	ARRRRRRRRR	Hirschmann et al., "An Approach to an Improved Antiinflammatory Steroid, The Synthesis of 11β, 17-Dihydroxy-3,20-dione-1,4-pregnadien-21-yl 2-Acetamido-2-deoxy-β-D-glucopyranoside" <i>Journal of the American Chemical Society</i> Vol. 86, 3903-3904 (1964)
KKF	ASSSSSSSSS	Hirtotani, M., and Furuyu, T., "Biotransformation of Testosterone and Other Androgens by Suspension Cultures of <i>Nicotiana Tabacum</i> 'Bright Yellow', " <i>Phytochemistry</i> 13:2135-2142 (1974).
KKF	ATTTTTTTTT	Holstein, S. A. et al., "Phosphonate and Bisphosphonate Analogues of Farnesyl Pyrophosphate as Potential Inhibitors of Farnesyl Protein Transferase," <i>Bioorg. Med. Chem.</i> 6:687-694, Elsevier Science Ltd. (1998).
KKF	AUUUUUUUUU	International Search Report for International Application No. PCT/GB00/01700, mailed 08/24/2000
KKF	AVVVVVVVVV	International Search Report for International Application No. PCT/GB01/00140, mailed June 27, 2001
KKF	WWWWWWWW	International Search Report for PCT/GB00/03865, mailed February 19, 2001
KKF	AXXXXXXXXX	Johnson et al., "Influence of Race or Ethnicity on Pharmacokinetics of Drugs" <i>Journal of Pharmaceutical Sciences</i> Vol. 86, No. 12, (1997)
KKF	AYYYYYYYYY	Jones et al., "An On-Line HPLC-Electrospray Ionization mass spectrometric method for the study of tamoxifen metabolism" <i>Journal of Chromatography A</i> , 722 (1996)249-255
KKF	AZZZZZZZZZ	Jones, C.D., et al., "Antiestrogens. #3 Estrogen Receptor Affinities and Antiproliferative Effects in MCF-7 Cells of Phenolic Analogues of Trioxifene, [3,4-Dihydro-2-(4-methoxyphenyl)-1-naphthalenyl] [4-[2-91-pyrrolidinyl]ethoxy]-phenyl]methanone," <i>J. Med. Chem.</i> 35:931-938, American Chemical Society (1992).
KKF	AAAAAAAAAA	Jordan et al., "Structural Requirements for the Pharmacological Activity of Nonsteroidal Antiestrogens in Vitro" <i>Molecular Pharmacology</i> , 26:272-278 (1984)
KKF	ABBBBBBBBB	Jusko et al., "Monitoring Prednisone and Prednisolone" <i>Therapeutic Drug Monitoring</i> 2:169-176 (1980)
<del>_____</del>	<del>AOOOOOOOOO</del>	<del>Kime, D.E., and Dolben, I.P., "Hormonal Changes During Induced Ovulation of the Carp, <i>Cyprinus carpio</i>," <i>General Comp. Endocrin.</i> 58:137-149 (1985)</del>

Examiner Signature 	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13227-008001	Application No. 09/759,371
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Michael F. Holick et al.	
		Filing Date January 16, 2001	Group Art Unit <del>1614</del> 1623
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
KCF	ADDDDDDDDD	Kocovsky, P., et al., "The Synthesis of Some New Steroid Glucosides," <i>Collection Czechoslov. Chem. Commun.</i> 38:3273 (1973).
KCF	AEFFFFFFFF	Kong, "Disposition of Methylprednisolone and Its Sodium Succinate Prodrug in Vivo and in Perfused Liver of Rats: Nonlinear and Sequential First-Pass Elimination" <i>Journal of Pharmaceutical Sciences</i> Vol. 80, Number 5, (1991)
KCF	AFEEEEEEEEE	Lien et al. <i>ther. Drug Monit.</i> 1995, 17(3), 259-65
KCF	AGGGGGGGGG	<del>Liggett, N.W. and Reid, D.M., "Osteoporosis and its management," <i>Hosp. Med.</i> 60:238-242, Mark Allen Publishing (April 1999).</del> Liggett et al. "Osteoporosis and Its Management" <i>Hosp. Med.</i> 60: 238-42 (April 1999)
KCF	AHHHHHHHHH	Lim et al., "A comparative study of tamoxifen metabolism in femal rat, mouse and human liver microsomes" <i>Carcinogenesis</i> Vol. 15 no. 4 pp.589-593, 1994
KCF	AIHHHHHHH	Lim et al., "High Performance Liquid Chromatography of Tamoxifen and Metabolites in Plasma and Tissues" <i>Biomedical Chromatography</i> , Vol. 7, 311-314 (1993)
KCF	AJJJJJJJJJ	Lim et al., "Identification of epoxide metabolites of tamoxifen by on-line liquid chromatography-electrospray ionization mass spectrometry" <i>Biochemical Society Transactions</i> (1994)22, 165S
KCF	AKKKKKKKKK	Loeb, J.A., "Functional Improvement in a Patient with Cerebral Calcinosis Using a Bisphosphonate," <i>Movement Disorders</i> 13:345-349, Movement Disorder Society (1998).
KCF	ALLLLLLLLLL	Magnetto, S. et al., "Additive Antitumor Activities of Taxoids in Combination with the Bisphosphonate Ibandronate Against Invasion and Adhesion of Human Breast Carcinoma Cells to Bone," <i>Int. J. Cancer</i> 83:263-269, Wiley-Liss, Inc. (October 1999).
KCF	MMMMMMMMMM	Matsui et al., "Comparative Studies on the Metabolic Hydrogenation of the Ring A in Testosterone and Its Conjugates by Male Rat Liver in Vitro" <i>Chem. Pharm. Bull.</i> 20(9)1913-1920 (1972)
KCF	ANNNNNNNNN	May et al., "Regulation of progesterone Receptor mRNA by Oestradiol and Antioestrogens in Breast Cancer Cell Lines" <i>J. steroid Biochem.</i> Vol. 33, No. 6, pp. 1035-1041, 1989.
KCF	AOOOOOOOOO	McCague et al. <i>Biochem. Pharmacol.</i> 1990, 39(9), 1459-65
KCF	APPPPPPPPPP	McClung, M.R., "New Developments in Osteoporosis," <i>Comp. Ther.</i> 23:798-803, The American Society of Contemporary Medicine and Surgery (1997).
KCF	AQOOOOOOOO	McDougal et al., "Induction of 16 $\alpha$ -/2-Hydroxyestrone Metabolite Ratios in MCF-7 Cells by pesticides, Carcinogens, and Antiestrogens Does Not Predict Mammary Carcinogens" <i>Environmental Health Perspectives</i> Vol. 106, No. 4, 203-206 (1998)
KCF	ARRRRRRRRR	McLeod et al., "A Glucocorticoid Prodrug Facilitates Normal Mucosal Function in Rat Colitis Without Adrenal Suppression" <i>Gas.</i> 1994;106:405-413
KCF	ASSSSSSSSS	McLeod et al., "Glucocorticoid -Dextran Conjugates as Potential Prodrugs for Colon-Specific Delivery: Hydrolysis in Rat Gastrointestinal Tract Contents" <i>Journal of Pharmaceutical Sciences</i> Vol. 83, No. 9, (1994)
KCF	ATTTTTTTTT	McLeod, et al., "Synthesis and chemical stability of glucocorticoid-dextran esters: potential prodrugs for colon-specific delivery" <i>International Journal of Pharmaceutics</i> , 92 (1993) 105-114
KCF	AUUUUUUUUU	Mellor, J.D., et al., "Steroid $\beta$ -D-Glucosidase activity in rabbit tissues," <i>J. Biol. Chem.</i> 246:4377-4380 (1971).
KCF	AVVVVVVVVV	Meriggola, M.C. et al., "An Oral Regimen of Cyproterone Acetate and Testosterone Undecanoate for Spermatogenic Suppression in Men," <i>Fert. Steril.</i> 68:844-850 (1997).
KCF	AWWWWWWWW	Nambara et al., "LII. Studies On Steroid Conjugates. VII. Gas Chromatography of Steroid N-Acetylglucosaminides" <i>Journal of Chromatography</i> 62 (1971) 369-372

Examiner Signature <i>KK Wanda</i>	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13227-008001	Application No. 09/759,371
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Michael F. Holick et al.	
		Filing Date January 16, 2001	Group Art Unit 1614 1623

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
KKF	AXXXXXXXXXX	Nitta et al., "Studies on Steroids. III, The Preparation of Steroid-21-yl-glucopyranosiduronamides." <i>Chem. Pharm. Bull</i> 12 (4) 450-453 (1964).
KKF	AYYYYYYYYY	Nolen III et al., "Steady-State Pharmacokinetics of Corticosteroid Delivery From Glucuronide Prodrugs in Normal and Colitic Rats" <i>Biopharmaceutics and Drug Disposition</i> Vol. 18:8, 681-695 (1997)
KKF	AZZZZZZZZZ	Nolen III, et al., "Budesonide-β-D-glucuronide: A Prodrug for Treatment of Ulcerative Colitis" <i>Journal of Pharmaceutical Sciences</i> , 84 (6): 667-681 (June 1995)
KKF	AAAAAAAAAA	Nolen III, et al., "Glucuronide Prodrugs for Colonic Delivery: Steady-State Kinetics in Conventional and Colitic Rates," <i>Proceed. Intern. Symp. Control. Rel. Bioact. Mater.</i> , 23:61-62 (1996)
KKF	ABBBBBBBBB	O'Donnell et al. <i>Xenobiotica</i> February 1998, 28(2), 153-166
KKF	ACCCCCCCCC	Patlas, N. et al., "Transplacental Effects of Bisphosphonates on Fetal Skeletal Ossification and Mineralization in Rats," <i>Teratology</i> 60:68-73, Wiley-Liss, Inc. (August 1999).
KKF	ADDDDDDDDD	Pauwels, "Therapeutic index for inhaled steroids" <i>Eu Respir Rev</i> 1997;7:50,366-368
KKF	AEEEEEEEEEE	Pending Non-Provisional United States Patent Application No. 09/565,122, Holick and Kanis, filed May 4, 2000.
KKF	AFEEEEEEEEE	Pending Non-Provisional United States Patent Application No. 09/680,272, Holick et al., filed October 6, 2000.
KKF	AGGGGGGGGG	Pending Non-Provisional United States Patent Application No. 09/759,371, Holick et al., filed January 16, 2001
KKF	AHHHHHHHHH	Pending U.S. Patent Application No. 09/680,266, filed October 6, 2000.
KKF	AIHHHHHHHH	Pending U.S. Patent Application No. 09/760,382, filed January 16, 2001
KKF	AJJJJJJJJJJ	Poon et al. <i>Drug Metab. Dispos.</i> 1993, 21(6), 1119-24.
KKF	AKKKKKKKKK	Rosen et al., "Multiple Myeloma and chronic lymphocytic leukemia" <i>Hematologic Malignancies</i> Vol. 2 No. 4, 275-282 (1995)
KKF	ALLLLLLLLLL	Ruenitz et al., "Comparative Fates of Clomiphene and Tamoxifen in the Immature Femal Rat" <i>Drug Metabolism and Disposition</i> Vol. 13, No. 5, 582-586 (1985)
KKF	AMMMMMMMMM	Ruenitz et al., "Estrogenic and Antiestrogenic Activity of Monophenolic Analogues of Tamoxifen, (Z)-2-[p-(1,2-Diphenyl-1-butenyl) phenoxy]-N,N-dimethylethylamine" <i>J. Med Chem.</i> 1982, 25,1056-1060
KKF	ANNNNNNNNN	Rungby et al., "Epidemiology of Osteoporosis: Implications for Drug Therapy" <i>Drugs &amp; Aging</i> Vol. 6 (pp. 421-500) 1995
KKF	AOOOOOOOOO	Russell, R.G.G. and Rogers, M.J., "Bisphosphonates: From the Laboratory to the Clinic and Back Again," <i>Bone</i> 25:9. 7-106, Elsevier Science Inc. (July 1999).
KKF	APPPPPPPPPP	Rutgeerts et al., "A Comparison of Budesonide with Prednisolone For Active Crohn's Disease" <i>The New England Journal of Medicine</i> Vol. 31 No. 13, 842-846 (1994)
KKF	AQQQQQQQQQ	Sauer et al., "Anomeric C-19-Steroid N-Acetylglucosaminides" <i>The Journal of Organic Chemistry</i> Vol. 34, No. 11,(1969)
KKF	ARRRRRRRRR	Schneider et al., "Thin-Layer Chromatography of Anomeric Steroid Tri-O-Acetyl-d-glucopyranosiduronic methyl Esters, D-Glucopyranoside Tetraacetates, and 2'-Acetamido-2'-Deoxy-Tri-O-Acetyl-D-Glucopyranosides" <i>Journal of Chromatography</i> 48 (1970) 509-514

Examiner Signature <i>KKF</i>	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 13227-008001	Application No. 09/759,371
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary)		Applicant Michael F. Holick et al.	
		Filing Date January 16, 2001	Group Art Unit 1614 1623
(37 CFR §1.98(b))			

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
KKF	ASSSSSSSSS	Schneider, J.J., "Preparation and properties of some new steroid $\beta$ -D-glucopyranosidases, $\beta$ -D-glucopyranosiduronic acids, and derivatives," <i>Carbohydr. Res.</i> 17:199-207 (1971).
KKF	ATTTTTTTTT	Sellers et al., "The use of pamidronate in three children with renal disease" <i>Pediatr. Nephrol</i> (1998) 12:778-781
KKF	AUUUUUUUUU	Shane, et al. "Prevention of Bone Loss After Heart Transplantation With Antiresorptive Therapy : A Pilot Study" <i>The Journal of Heart and Lung Transplantation</i> Vol. 17 No. 11, 1089-1096 (1998)
KKF	AVVVVVVVVV	Singer, F.R. and Minoofar, P.N., "Bisphosphonates in the Treatment of Disorders of Mineral Metabolism," <i>Advances Endocrinol. Metabol.</i> 6:259-288, Mosby-Year Book, Inc. 1995.
KKF	WWWWWWWW	Spillman et al., "BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen" <i>Oncogene</i> (1996) 13,1639-1645
KKF	AXXXXXXXXX	Surrey, "Add-Back Therapy: Extending Safety and Efficacy of GnRH Analogues in the Gynecologic Patient" <i>Gynecol Obstet Invest</i> 1998;45(suppl 1):31-34
KKF	AYYYYYYYYY	Taburet et al, "Pharmacokinetic Optimisation of Asthma Treatment" <i>Clin. Pharmacokinet.</i> 26 (5):396-418, 1994
KKF	Tindall	Tindall, D.J., et al., "Structural requirements for Steroid binding to androgen binding proteins," <i>Int. J. Androl. Suppl.</i> 2d:434-448 (1978).
		<del>Tozer, "Colon Drug Delivery in Perspective" PDD 7126</del>
KKF	ABBBBBBBBB	Tozer, et al. "Colon-Specific delivery of Dexamethason from a Glucoside Prodrug in the Guinea Pig" <i>Pharmaceutical Research</i> , Vol. 8, No. 4, 1991
KKF	ACCCCCCCCC	Tumeh, S.S., "Scintigraphy in the Evaluation of Arthropathy," <i>Radiologic Clinics North Am.</i> 34:215-231, W.B. Saunders Company (1996).
KKF	DDDDDDDDDD	Vojtiskova, M., et al., "Biological Activity of Hormonally Active and Non-Active Androgen Derivatives," <i>Intl. J. Immunopharmac.</i> 4:469-474 (1982).
	AEEEEEEEEEE	Watanabe et al. <i>J. Chromatogr.</i> 1989, 497, 169-80.
KKF	AFFFFFFFFFFF	Watts, "Postmenopausal Osteoporosis" <i>CME Review Article</i> Vol. 54, No. 8 (1999)
KKF	GGGGGGGGGG	Wilson et al, "Systemic Bioactivity Profiles of Oral Prednisolone and Nebulized Budesonide in Adult Asthmatics" <i>Chest</i> 114/4/1022-1027 (1998)
KKF	HHHHHHHHHH	Wu, F.C. W., et al., "Oral Progestogen Combined with Testosterone as a Potential Male Contraceptive: Additive Effects Between Desogestrel and Testosterone Enanthate in Suppression of Spermatogenesis, Pituitary-Testicular Axis, and Lipid Metabolism," <i>J. Clin. Endocrin. Met.</i> 84:112-122 (January 1999).
KKF	IIIIIIIIII	Xie et al., "Estrogen Induces Adenosine Deaminase Gene Expression in MCF-7 Human Breast Cancer Cells: Role of Estrogen Receptor-Sp1 Interactions" <i>Endocrinology</i> Vol. 140, No. 1, 219-227 (1999)
KKF	JJJJJJJJJJ	Yesil, S. et al., "Further hearing loss during osteoporosis treatment with etidronate," <i>Postgrad. Med. J.</i> 74:363-364, British Medical Journal Publishing Group (1998).
KKF	KKKKKKKKKK	Zhengwei, Y., et al., "Immature Spermatids are Not Prevalent in Semen From Men Who are receiving Androgen-Based Contraceptive Regimens," <i>Fert. Steril.</i> 69:89-95 (1998)

Examiner Signature 	Date Considered 12-13-02
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	